Comparative Pharmacology
Head-to-head clinical analysis: TENORETIC 100 versus TENORMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TENORETIC 100 versus TENORMIN.
TENORETIC 100 vs TENORMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tenoretic 100 is a combination of atenolol (a cardioselective beta-1 adrenergic receptor antagonist) and chlorthalidone (a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule). Atenolol reduces heart rate, cardiac output, and blood pressure by blocking beta-1 receptors; chlorthalidone reduces plasma volume and peripheral resistance.
Selective beta-1 adrenergic receptor antagonist; blocks catecholamine effects at beta-1 receptors, reducing heart rate, myocardial contractility, and blood pressure.
One tablet orally once daily, each tablet containing atenolol 100 mg and chlorthalidone 25 mg. May be increased to 2 tablets once daily if needed.
Hypertension: 50 mg orally once daily; may increase to 100 mg once daily. Angina: 50 mg orally once daily; may increase to 100 mg once daily. Acute MI: 5 mg IV over 5 minutes, followed by 50 mg orally 15 minutes later, then 50 mg orally 12 hours later, then 100 mg orally once daily.
None Documented
None Documented
Atenolol: terminal half-life 6-7 h (up to 14 h in severe renal impairment); Chlorthalidone: 40-60 h (long-acting diuretic).
6-7 hours (terminal); prolonged to 16-27 hours in renal impairment (CrCl <35 mL/min).
Tenoretic 100 (atenolol 100 mg + chlorthalidone 25 mg): Atenolol: ~85% renal unchanged, <10% fecal; Chlorthalidone: ~65% renal unchanged, remainder biliary/fecal.
Renal elimination of unchanged drug (40-50%) and hepatic metabolism to inactive metabolites excreted in urine; <5% fecal.
Category C
Category C
Beta blocker/thiazide diuretic combination
Beta blocker